Status: Not yet recruiting
Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine
This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella vaccine co-administered with MMR vaccine or DTaP vaccine. The secondary objective is to evaluate the safety of the vaccines when administered simultaneously.
Participants needed: 720
Trial details
Phase: Phase 4Age: 18-24Biological sex: AllType: InterventionalSponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.Updated: Mar 24, 2025Locations: 1
Eligibility criteria
Infants aged 18-24 months; [+4]
Having a history of previous varicella vaccination; [+14]